Repligen Corporation (RGEN) Given Consensus Recommendation of “Buy” by Brokerages
Repligen Corporation (NASDAQ:RGEN) has earned an average recommendation of “Buy” from the eight research firms that are currently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $41.00.
RGEN has been the topic of several research reports. Zacks Investment Research upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $43.00 price target on the stock in a research note on Thursday, May 11th. BidaskClub downgraded shares of Repligen Corporation from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, June 14th. Janney Montgomery Scott upped their price target on shares of Repligen Corporation from $42.00 to $47.00 in a research note on Friday, June 23rd. Jefferies Group LLC restated a “hold” rating and issued a $40.00 price target (up from $33.00) on shares of Repligen Corporation in a research note on Wednesday, June 28th. Finally, William Blair initiated coverage on shares of Repligen Corporation in a research note on Friday, July 21st. They issued an “outperform” rating on the stock.
Shares of Repligen Corporation (NASDAQ:RGEN) opened at 42.39 on Wednesday. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of 82.95 and a beta of 1.30. Repligen Corporation has a 52 week low of $26.16 and a 52 week high of $46.81. The stock has a 50 day moving average of $41.55 and a 200-day moving average of $37.47.
Repligen Corporation (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.05. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The business had revenue of $32.40 million for the quarter, compared to the consensus estimate of $31.72 million. During the same period in the prior year, the company posted $0.16 earnings per share. Repligen Corporation’s revenue was up 11.0% compared to the same quarter last year. Equities research analysts expect that Repligen Corporation will post $0.59 earnings per share for the current year.
A number of large investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. purchased a new stake in Repligen Corporation during the first quarter valued at $103,000. Victory Capital Management Inc. boosted its stake in Repligen Corporation by 76.6% in the first quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 1,475 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Repligen Corporation during the second quarter valued at $120,000. Oppenheimer Asset Management Inc. purchased a new stake in Repligen Corporation during the second quarter valued at $123,000. Finally, State of Alaska Department of Revenue boosted its stake in Repligen Corporation by 2.2% in the first quarter. State of Alaska Department of Revenue now owns 3,740 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 80 shares in the last quarter. 97.91% of the stock is owned by institutional investors and hedge funds.
Repligen Corporation Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.